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A bs tr ac t
Background
Daily inhaled glucocorticoids are recommended for young children at risk for asthma 
exacerbations, as indicated by a positive value on the modified asthma predictive index 
(API) and an exacerbation in the preceding year, but concern remains about daily ad-
herence and effects on growth. We compared daily therapy with intermittent therapy.
Methods
We studied 278 children between the ages of 12 and 53 months who had positive 
values on the modified API, recurrent wheezing episodes, and at least one exacerba-
tion in the previous year but a low degree of impairment. Children were randomly 
assigned to receive a budesonide inhalation suspension for 1 year as either an inter-
mittent high-dose regimen (1 mg twice daily for 7 days, starting early during a 
predefined respiratory tract illness) or a daily low-dose regimen (0.5 mg nightly) 
with corresponding placebos. The primary outcome was the frequency of exacerba-
tions requiring oral glucocorticoid therapy.
Results
The daily regimen of budesonide did not differ significantly from the intermittent 
regimen with respect to the frequency of exacerbations, with a rate per patient-year for 
the daily regimen of 0.97 (95% confidence interval [CI], 0.76 to 1.22) versus a rate of 
0.95 (95% CI, 0.75 to 1.20) for the intermittent regimen (relative rate in the intermit-
tent-regimen group, 0.99; 95% CI, 0.71 to 1.35; P = 0.60). There were also no significant 
between-group differences in several other measures of asthma severity, including the 
time to the first exacerbation, or adverse events. The mean exposure to budesonide 
was 104 mg less with the intermittent regimen than with the daily regimen.
Conclusions
A daily low-dose regimen of budesonide was not superior to an intermittent high-
dose regimen in reducing asthma exacerbations. Daily administration led to great-
er exposure to the drug at 1 year. (Funded by the National Heart, Lung, and Blood 
Institute and others; MIST ClinicalTrials.gov number, NCT00675584.)
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R ecurrent wheezing episodes in pre-school-age children are usually triggered by respiratory tract infections,1,2 which often 
progress to severe exacerbations requiring sys-
temic glucocorticoids3 and frequent use of health 
care services.4,5 In children under the age of 5 years 
who had at least four wheezing episodes during 
the previous year and positive values on the mod-
ified asthma predictive index (API) (indicating an 
increased likelihood of persistent asthma in the 
future),6,7 the National Asthma Education and Pre-
vention Program Expert Panel Report 3 (EPR-3) 
recommends the initiation of long-term daily in-
haled glucocorticoid therapy8 on the basis of the 
results of the Childhood Asthma Research and Edu-
cation (CARE) Network Prevention of Early Asth-
ma in Kids (PEAK) trial (ClinicalTrials.gov number, 
NCT00272441).9 In a post hoc analysis, investi-
gators in the PEAK trial found that daily therapy 
with inhaled glucocorticoids most benefited chil-
dren who had had at least one exacerbation re-
quiring emergency or hospital care during the 
previous year.10
Daily use of inhaled glucocorticoids in the 
PEAK trial was associated with a small but sig-
nificant reduction in height growth, as compared 
with placebo, a reduction that was only partially 
reversed during a 1-year observation period after 
the discontinuation of study treatments.9 Concern 
about growth retardation and parental resistance 
to a daily regimen of inhaled glucocorticoids for 
young children, who usually have only episodic 
but often severe symptoms, stimulated a search 
for alternative strategies — specifically, intermit-
tent therapy with inhaled glucocorticoids. Inter-
mittent 7-day courses of high-dose nebulized 
budesonide, as compared with placebo, initiated 
during respiratory tract illnesses led to significant 
reductions in the severity of respiratory symp-
toms, without affecting linear growth, in the 
CARE Network Acute Intervention Management 
Strategies (AIMS) study (NCT00000622); benefits 
were most apparent in children with positive values 
on the modified API.11 In confirmation of these 
findings, preemptive use of intermittent high-dose 
fluticasone during upper respiratory illness re-
duced exacerbations requiring oral glucocorti-
coids in young children with moderate-to-severe, 
virus-induced wheezing.12
We conducted the Maintenance and Intermit-
tent Inhaled Corticosteroids in Wheezing Toddlers 
(MIST) trial to determine whether a daily low-dose 
regimen of budesonide would be superior to an 
intermittent high-dose regimen in young children 
who had positive values on the modified API, 
along with recurrent wheezing, high-risk asthma 
(≥1 exacerbation in the previous year), and low 
impairment (infrequent use of albuterol and in-
frequent night awakenings between episodes).
Me thods
Study Patients
We enrolled children between the ages of 12 and 
53 months who met all the following criteria: dur-
ing the previous year, they had at least four epi-
sodes of wheezing (or three episodes of wheez-
ing and controller use for ≥3 months), positive 
values on the modified API,7 and at least one ex-
acerbation requiring the use of systemic gluco-
corticoids, urgent or emergency care, or hospital-
ization, and during a 2-week run-in period, they 
had fewer than 3 days per week of albuterol use 
and fewer than 2 nights with awakening. Children 
were excluded from the study if they had received 
more than six courses of oral glucocorticoids or 
had been hospitalized more than two times for 
wheezing during the previous year. (For additional 
details on inclusion and exclusion criteria, see the 
Supplementary Appendix, available with the full 
text of this article at NEJM.org.)
Study Design
The study, which was conducted at seven sites, 
was a randomized, double-blind, parallel-group 
trial. During a 2-week run-in period, all patients 
received nightly placebo doses of budesonide in-
halation suspension (Pulmicort Respules, Astra-
Zeneca) and as-needed albuterol, followed by a 
52-week treatment period. The full protocol and 
statistical analysis plan are available at NEJM.org. 
We compared the use of budesonide inhalation 
suspension given in a daily low-dose regimen 
with an intermittent high-dose regimen,13-18 with 
matching placebos (Fig. 1A). Specific procedures 
that were performed at all visits are detailed in 
Figure S1 in the Supplementary Appendix. The 
institutional review board at each center approved 
the study. Parents or guardians (hereafter re-
ferred to as parents for simplicity, unless other-
wise noted) provided written informed consent.
Intermittent high-dose treatments were start-
ed for an identified respiratory tract illness on 
the basis of a published education program (see 
the Supplementary Appendix).11,19 Parents began 
a 7-day course of intermittent study medication 
The New England Journal of Medicine 
Downloaded from nejm.org at WASHINGTON UNIV SCH MED MEDICAL LIB on May 27, 2014. For personal use only. No other uses without permission. 
 Copyright © 2011 Massachusetts Medical Society. All rights reserved. 
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
n engl j med 365;21 nejm.org november 24, 20111992
at the onset of symptoms or signs of a respiratory 
tract illness that they identified as their child’s 
usual starting point before the development of 
wheezing (Fig. S2 in the Supplementary Appendix). 
These individualized symptoms or signs were re-
assessed at all study visits. Parents contacted 
study staff within 72 hours after starting treat-
ment kits for respiratory tract illness, in order to 
summarize the events that defined the illness. 
In daily diaries, parents reported symptoms (e.g., 
nocturnal and daytime coughing, wheezing, dif-
ficulty breathing, and symptoms interfering with 
activities, with the severity of each scored from 
0 to 5 and with higher scores indicating greater 
severity),20 medications, health care visits, and ab-
sences from day care or preschool or parental work.
Outcome Measures
The primary outcome measure was the frequency 
of exacerbations, which was defined as the num-
ber of courses of an oral glucocorticoid (predniso-
lone) started for acute wheezing after consultation 
with a physician (by telephone or in person) on the 
basis of a specific published protocol9,11 during 
the 12-month treatment period (see the Supplemen-
tary Appendix). About 30% of courses of an oral 
glucocorticoid were not initiated by the study team. 
Secondary prespecified risk outcomes included 
the time to exacerbations, rate of treatment fail-
ure, rate of wheezing-related health care utiliza-
tion, and growth effects.7 Secondary prespecified 
impairment outcomes included the number of 
episode-free days,11 symptom severity during a 
respiratory tract illness,11,20 absences related to 
respiratory symptoms, albuterol use, quality of 
life according to the Infant Toddler Quality of 
Life questionnaire,21 and levels of fractional ex-
haled nitric oxide22 (Fig. S1 in the Supplementary 
Appendix). Adherence was determined by means of 
diary recordings of budesonide use. Analyses also 
examined the relationship between specific nasal 
respiratory viruses and respiratory tract illnesses.1
Study Oversight
The study was funded by the National Heart, Lung, 
and Blood Institute and was approved by its pro-
tocol review committee and data and safety mon-
itoring board. AstraZeneca donated budesonide 
and matching placebo and reviewed the protocol 
with minor comments and the manuscript with-
out commenting; the company had no other role 
in the study. The authors are fully responsible for 
the study design and data (collection, analysis, com-
pleteness, accuracy, and interpretation), as well as 
for the fidelity of the report to the study protocol.
Statistical Analysis
The study was designed as a superiority trial of a 
daily low-dose regimen of budesonide, as compared 
with an intermittent high-dose regimen, since pre-
vious CARE trials had shown the efficacy of both 
regimens versus placebo in similar high-risk, low-
impairment cohorts.9,11 Baseline characteristics 
were summarized with the use of descriptive statis-
tics. We used the exact Wilcoxon–Mann–Whitney 
test, stratified according to study center and age 
group, to determine statistical significance.
Although the determination of statistical sig-
nificance for the treatment comparison was based 
on a nonparametric test, the primary research 
question was framed in terms of the annual rate 
of exacerbations. For the primary parametric anal-
Figure 1 (facing page). Study Design and Enrollment.
Panel A shows the study design and treatments. Intermittent high-dose nebulized budesonide inhalation suspension 
was administered at a dose of 1 mg twice daily in the form of Pulmicort Respules for 7 days at the onset of a predefined 
respiratory tract illness. A matched placebo was administered once nightly on all other days. Daily low-dose nebulized 
budesonide inhalation suspension was administered at a dose of 0.5 mg once nightly, also in the form of Pulmicort 
Respules. During respiratory tract illnesses, an appropriately matched morning placebo was used for 7 days. To main-
tain blinding during respiratory tract illnesses, daily treatments were discontinued for 7 days and respiratory illness 
kits that were based on the study-group assignment were administered for 7 days. After 7 days, regular daily treat-
ments were restarted. Open-label rescue albuterol was administered per protocol during a respiratory tract illness and 
as needed. Study medications were administered with the use of a Pari Ultra II compressor with a Pari LC Sprint re-
usable nebulizer and a mask (Bubbles the Fish II or Pari Baby mask), if needed, or a mouthpiece, depending on the 
age of the child. Rescue albuterol was administered at a dose of 180 μg per treatment by metered-dose inhalation 
 (Ventolin HFA, GlaxoSmithKline) through AeroChamber Z-STAT Plus with FlowSIGnal Whistle with ComfortSeal Mask 
(Monaghan Medical) or a solution of 2.5 mg of albuterol per treatment by nebulization according to protocol during 
a respiratory tract illness (four times daily, while the child was awake, for the first 48 hours) and as needed. Panel B 
shows the numbers of patients who were enrolled in the study, underwent randomization, and completed the study.
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ysis, we used a negative binomial regression model 
incorporating actual follow-up time so that we 
could appropriately estimate the rate of exacerba-
tion per patient-year. Secondary analyses exam-
ined the effect of treatment on other outcomes. 
For counted outcomes, such as unscheduled health 
care visits, a similar model was applied. We used 
analysis of covariance for outcomes that were mea-
sured on a continuous scale, such as linear growth, 
and appropriate transformations were applied for 
278 Underwent randomization before end
of enrollment in July 2009
450 Children were enrolled between
August 2008 and July 2009
172 Were excluded during run-in
54 Had excessive asthma symptoms
19 Had negative asthma predictive index values
18 Were ineligible at the first visit
18 Had adherence issues
16 Had consent withdrawn
16 Had an asthma exacerbation
13 Used other asthma medications
7 Were lost to follow-up
4 Were ineligible by physician discretion
1 Had a serious adverse event
6 Had other reasons
139 Were assigned to intermittent-
regimen group
139 Were assigned to daily-regimen
group
26 Did not complete study
23 Were lost to follow-up, or
caregivers were no longer
interested, were unable
to make visits, or with-
drew consent




1 Had treatment failure
39 Did not complete study
26 Were lost to follow-up, or
caregivers were no longer
interested, were unable
to make visits, or with-
drew consent
3 Caregivers were dissatis-
fied with asthma control
3 Had physician-initiated
terminations
2 Had side effects
4 Had treatment failure
1 Had another reason  
113 Completed study by August 2010 100 Completed study by August 2010
Run-in: 2 Weeks Treatment Phase: 52 Weeks
















Budesonide (0.5 mg) in p.m. 
Budesonide (1.0 mg) in a.m. 
Budesonide (1.0 mg) in p.m. 
B
A
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any outcome that had a skewed distribution. We 
used a proportional-hazards regression model for 
time-to-event outcomes, such as the time to the 
first exacerbation. The total exposure to budeso-
nide in an intention-to-treat model is described in 
the Supplementary Appendix.
For sample-size determination, we used the 
results of the PEAK7 and AIMS11 trials to estimate 
exacerbation rates. The sample size that was re-
quired for a power of 90% was determined for a 
range of exacerbation rates, from 0.6 to 1.2 per 
year. On the basis of a 10% dropout rate, we cal-
culated that a sample of 250 children would pro-
vide a power of 90% (225 total patient-years) if the 
relative exacerbation rate for one treatment group 
was at least 40% lower than the rate in the other 
group. During the course of the trial, it became 
evident that the actual noncompletion rate might 
be as high as 20%. With approval from the data 
and safety monitoring board and the institutional 
review boards, 28 additional patients underwent 
randomization, which preserved a power of 90%, 
since data from 235 patient-years would be avail-
able for the intention-to-treat analysis.
All analyses were performed with the use of SAS 
statistical software, version 9.1, and were adjusted 
for the randomization strata. A two-sided P value 
of less than 0.05 for between-group comparisons 
was considered to indicate statistical significance, 




Of the 450 children who were originally enrolled 
in the study, 172 were excluded during the run-in 
period. A total of 278 children underwent random-
ization, and 213 completed the study (Fig. 1B). The 
two study groups had similar demographic and 
clinical characteristics (Table 1). The noncomple-
tion rate was 23.3%, with no significant differences 
between the two groups (Tables S1 and S2 in the 
Supplementary Appendix). Reported rates of adher-
ence to treatment and diary entries were high and 
similar in the two groups (Table 2). Of the reports 
of treatments for respiratory tract illness, 95.6% 
were made by mothers, 3.9% by fathers, 0.4% by 
grandparents, and 0.1% by legal guardians.
Primary Outcome
There was no significant difference between a 
daily regimen of budesonide and an intermittent 
regimen with respect to the frequency of exacerba-
tions requiring the use of rescue oral glucocorti-
coids, with a rate per patient-year of 0.97 (95% confi-
dence interval [CI], 0.76 to 1.22) in the daily-regimen 
group versus a rate of 0.95 (95% CI, 0.75 to 1.20) 
in the intermittent-regimen group (relative rate in 
the intermittent-regimen group, 0.99; 95% CI, 0.71 
to 1.35; P = 0.60) (Fig. 2A and Table 2). There was 
also was no significant between-group difference 
with respect to the time to the first exacerbation 
(hazard ratio, 0.97; 95% CI, 0.76 to 1.22; P = 0.87) 
(Fig. 2B), the time to the second exacerbation (haz-
ard ratio, 0.79; 95% CI, 0.49 to 1.32; P = 0.38), or the 
frequency of treatment failure (P = 0.12).
Secondary Prespecified Outcomes
The distribution of the type of symptoms (e.g., 
coughing or wheezing) that led caregivers to recog-
nize a respiratory tract illness and initiate treatment 
was similar in the two study groups (P = 0.60) (Ta-
ble S3 in the Supplementary Appendix). There were 
also no significant differences in the rates of re-
spiratory tract illness per patient-year (3.27 with 
the daily regimen and 3.61 with the intermittent 
regimen, P = 0.30), respiratory tract illnesses in 
which prednisolone was administered (0.26 with 
the daily regimen and 0.24 with the intermittent 
regimen, P = 0.50) (Table 2), the frequency of treat-
ments for respiratory tract illnesses (P = 0.30) 
(Fig. 2C), and the time to the first treatment for 
respiratory tract illness (P = 0.16) (Fig. 2D). Most 
exacerbations occurred during treated respiratory 
tract illnesses, with 102 of 111 exacerbations dur-
ing treated illnesses (91.9%) in the daily-regimen 
group and 105 of 115 exacerbations during treated 
illnesses (91.3%) in the intermittent-regimen group. 
Similarly, there were no significant between-group 
differences in symptom scores during respiratory 
tract illnesses (Fig. 3, and Table S4 in the Supple-
mentary Appendix) or during exacerbations (Fig. S3 
in the Supplementary Appendix).
The proportion of episode-free days across 
the study was 78%, and the rate of wheezing-
related unscheduled physician visits was approxi-
mately 2.40 visits per patient-year in the two 
study groups (Table 2). The rate of absences for 
children and parents (from day care and work, 
respectively), the proportion of days with al bu-
ter ol use (Table 2), and changes in most quality-
of-life measures (Table S4 in the Supplementary 
Appendix) were similar in the two study groups. 
Given that measurements of fractional exhaled 
nitric oxide were unsuccessful in 36% of chil-
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dren at baseline, particularly in the youngest 
children, changes in values for fractional ex-
haled nitric oxide were not reported. The fre-
quency and distribution of respiratory viruses 
in nasal secretions during two regularly sched-
uled clinic visits and during respiratory tract ill-
nesses were similar in the two groups (Table 2, 
and Table S5 in the Supplementary Appendix).
Safety
The total exposure to budesonide over the course 
of the study was less in the intermittent-regimen 








Age of 12–32 mo — no. (%) 127 (45.7) 64 (46.0) 63 (45.3)
Male sex — no. (%) 192 (69.1) 102 (73.4) 90 (64.7)
White race — no. (%)† 173 (62.2) 91 (65.5) 82 (59.0)
Height — cm 94.2±9.1 94.0±9.1 94.5±9.0
Weight — kg 15.2±3.1 15.0±3.0 15.5±3.1
Head circumference — cm 50.0±1.9 50.1±2.0 49.9±1.9
Physician diagnosis of asthma — no. (%) 198 (71.2) 99 (71.2) 99 (71.2)
No. of wheezing episodes in past year 6.7±5.4 7.0±5.9 6.4±4.7
No. of urgent or emergency visits in past year 4.8±4.2 4.6±4.2 5.0±4.1
Hospitalizations in past year — no. (%) 53 (19.1) 26 (18.7) 27 (19.4)
Tobacco-smoke exposure from birth — no. (%) 114 (41.0) 55 (39.6) 59 (42.4)
Medication use in past year — no. (%)
Asthma controller 194 (69.8) 100 (71.9) 94 (67.6)
Inhaled glucocorticoid 189 (68.0) 96 (69.1) 93 (66.9)
Oral glucocorticoid 210 (75.5) 110 (79.1) 100 (71.9)
Allergy — no./total no. (%)
Food sensitivity 95/273 (34.8) 50/135 (37.0) 45/138 (32.6)
Any aeroallergen sensitivity 161/276 (58.3) 82/137 (59.9) 79/139 (56.8)
IgE — IU/ml
Median 58 50 61
Interquartile range 21–186 20–195 25–179
Eosinophils ≥4% — no./total no. (%) 123/260 (47.3) 61/132 (46.2) 62/128 (48.4)
Eczema — no. (%) 146 (52.5) 76 (54.7) 70 (50.4)
Allergic rhinitis — no. (%) 105 (37.8) 50 (36.0) 55 (39.6)
Parental asthma — no./total no. (%) 171/266 (64.3) 85/131 (64.9) 86/135 (63.7)
Exhaled nitric oxide ≥10 ppb — no./total no. (%) 78/178 (43.8) 36/82 (43.9) 42/96 (43.8)
Episode-free days during run-in period — % 67±30 66±30 68±29
Diary scores during run-in period‡
Coughing 0.4±0.4 0.4±0.5 0.4±0.4
Wheezing 0.1±0.3 0.2±0.3 0.1±0.3
Trouble breathing 0.1±0.3 0.1±0.3 0.1±0.2
Interference with activities 0.1±0.2 0.1±0.2 0.1±0.3
General health perceptions from ITQOL§ 59.2±14.1 59.0±14.8 59.4±13.5
Any nasal virus identified — no. (%) 148 (53.2) 72 (51.8) 76 (54.7)
* Plus–minus values are means ±SD. There were no significant differences between the two groups.
† Race was determined by parents or guardians.
‡ Scores range from 0 to 5, with higher scores indicating more severe symptoms. Scores were calculated from diaries as 
means ±SD for the 2-week run-in period.
§ The scores on the Infant Toddler Quality of Life (ITQOL) questionnaire range from 0 to 100, with higher scores indicating 
better health.
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group (45.7 mg; 95% CI, 38.9 to 52.8) than in the 
daily-regimen group (149.9 mg; 95% CI, 140.1 
to 159.6), with an average reduction of 104 mg 
(95% CI, -116 to -92) in the intermittent-regimen 
group. Between-group differences in changes in 
height, weight, and head circumference were not 
significant (Table 2, and Fig. S4 in the Supplemen-
tary Appendix).





(N = 139) Treatment Effect†
Event Rate/Person-Yr (95% CI) Relative Rate (95% CI)
No. of prednisolone courses for asthma‡ 0.95 (0.75 to 1.20) 0.97 (0.76 to 1.22) 0.99 (0.71 to 1.35)
No. of treatments for respiratory tract illness‡ 3.61 (3.13 to 4.16) 3.27 (2.82 to 3.79) 1.10 (0.91 to 1.35)
No. of urgent care visits for asthma‡ 2.37 (1.89 to 2.97) 2.40 (1.91 to 3.02) 0.99 (0.72 to 1.35)





Respiratory tract illnesses in which prednisolone was administered‡ 0.24 (0.19 to 0.29) 0.26 (0.21 to 0.32) 0.90 (0.68 to 1.19)
Respiratory tract illnesses with virus detected in nasal sample 0.83 (0.74 to 0.92) 0.83 (0.74 to 0.93) 1.00 (0.85 to 1.17)
Respiratory tract illnesses with exacerbations and nasal virus  
detected





Episode-free days — % 78 (75 to 80) 78 (76 to 81) −0.7 (−4.0 to 2.0)
Episode-free days, excluding days during treatment for respiratory 
tract illness — %
85 (82 to 87) 84 (82 to 86) 0.5 (−3.0 to 4.0)
Days with albuterol use — % 6 (5 to 7) 5 (4 to 6) 0.4 (−1.0 to 2.0)
Annualized days of treatment with budesonide — no. 24 (21 to 27) 337 (330 to 344) −314 (−322 to −306)
Cumulative dose of budesonide — mg 46 (39 to 53) 150 (140 to 160) −104 (−116 to −92)
Change in height from baseline
Value — cm 8.01 (7.71 to 8.30) 7.76 (7.45 to 8.07) 0.26 (−0.17 to 0.68)
Percentile 4.04 (2.07 to 6.00) 2.39 (0.14 to 4.64) 1.65 (−1.34 to 4.63)
z score 0.12 (0.04 to 0.20) 0.10 (0.02 to 0.18) 0.02 (−0.10 to 0.13)
Change in weight from baseline
Value — kg 2.54 (2.37 to 2.71) 2.38 (2.20 to 2.55) 0.16 (−0.08 to 0.41)
Percentile 4.11 (2.07 to 6.16) 0.73 (−1.39 to 2.85) 3.38 (0.43 to 6.33)
z score 0.15 (0.07 to 0.22) 0.05 (−0.03 to 0.13) 0.10 (−0.01 to 0.21)
Change in head circumference from baseline
Value — cm 0.92 (0.79 to 1.05) 0.87 (0.74 to 1.00) 0.05 (−0.14 to 0.23)
Percentile −1.20 (−3.45 to 1.04) −3.59 (−6.67 to −0.51) 2.39 (−1.43 to 6.20)
z score −0.07 (−0.17 to 0.03) −0.13 (−0.24 to −0.02) 0.06 (−0.09 to 0.21)
Days with diary-card adherence — % 83 (78 to 88) 88 (84 to 92) −5 (−11 to 2)
Days with adherence to budesonide or placebo — %§
Daily 94 (93 to 96) 95 (94 to 96) −1 (−2 to 1)
During respiratory tract illness 81 (75 to 87) 82 (75 to 89) −1 (−10 to 8)
* All outcomes have been adjusted for age and clinical center. Growth was measured in 113 children in the intermittent-regimen group and 
110 in the daily-regimen group. All other outcomes included data from the entire cohort.
† The treatment effect was calculated as the value in the intermittent-regimen group divided by the value in the daily-regimen group.
‡ Models were also adjusted for sex, race, and atopy, since results were similar with adjustment for age and clinical center only.
§ Treatment adherence was evaluated on days for which diary data were available.
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There were no deaths. The proportions of pa-
tients with serious adverse events (including all 
hospitalizations) and nonserious adverse events 
did not differ significantly in the two study groups 
(Table S6 in the Supplementary Appendix). Four 
children in the daily-regimen group and five in 
the intermittent-regimen group were hospitalized 
for asthma exacerbations. Other reasons for hos-
pitalization were pneumonia, gastroenteritis, and 
diarrhea (one patient each) in the daily-regimen 
group and concussion, gastroenteritis, influenza, 
tonsillectomy, and motor-vehicle accident (one pa-
tient each) in the intermittent-regimen group.
Discussion
We report that a daily low-dose regimen of bu des-
onide inhalation suspension was not superior to 
an intermittent high-dose regimen, administered 
for 7 days during a predefined respiratory tract 
illness, with respect to the frequency of exacerba-
tions (the primary outcome) in preschool-age chil-
dren at risk for asthma and future exacerbations. 
In addition, there was no significant between-
group difference in respiratory symptoms (symp-
tom severity during respiratory tract illnesses, 
episode-free days, and bronchodilator use) or qual-
ity of life. These findings occurred in the context 
of similar rates of reported adherence and identi-
fication of nasal viruses in the two study groups.
The treatment of preschool-age children with 
recurrent wheezing is complex, since most of these 
children do not have persistent asthma, as defined 
by regular symptoms, and the diagnosis is diffi-
cult to confirm. U.S. guidelines8 recognize this 
complexity in regard to diagnosis and management 
and recommend daily therapy with inhaled gluco-
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Figure 2. Exacerbations of Wheezing and Respiratory Tract Illness.
P values are based on exact Wilcoxon–Mann–Whitney tests for Panels A and C and on Wald tests from a proportional-hazards regression 
model for Panels B and D. All comparisons have been adjusted for clinical center and age.
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dren with recurrent wheezing and risk factors 
for persistent asthma (i.e., positive values on the 
modified API),8 although this treatment does not 
alter the course of the disease after the inhaled 
glucocorticoids are discontinued.9 Guidelines of 
the Global Initiative for Asthma (GINA)23 also rec-
ommend daily controller therapy, including the use 
of inhaled glucocorticoids, for young children with 
intermittent wheezing, a history suggestive of 
asthma, and at least three wheezing episodes in 
the previous year. The guidelines caution against 
the use of daily high-dose therapy with inhaled 
glucocorticoids for prolonged periods, given the 
reported effect of such use on growth, and advise 
using the lowest dose necessary for asthma con-
trol.8 In this context, the inability to show the su-
periority of a daily low-dose regimen of bu des onide 
over an intermittent high-dose regimen may be 
important in the preparation of future guidelines.
The efficacy of daily low-dose inhaled glucocor-
ticoids, as compared with placebo, has been docu-
mented in studies ranging from 1.5 to 12 months 
and involving preschool-age children with positive 
values on the modified API,9 risk factors for asth-
ma,24-26 frequent recurrent wheezing or asthma 
symptoms,27,28 or physician-diagnosed asthma.13,29 
A recent meta-analysis30 and both the EPR-3 
national guidelines8 and GINA guidelines23 for 
infants and preschool-age children support these 
findings. In the PEAK trial, the daily low-dose in-
haled glucocorticoid that was shown to be effica-
cious was fluticasone administered in a metered-
dose inhaler, but there has been no evidence that 
efficacy differs when other inhaled glucocorticoids 
are used in clinically similar doses.8,10 In preschool-
age children who entered a trial with frequent 
symptoms, the percentage of symptom-free days 
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glucocorticoids than among those receiving pla-
cebo, but the comparison between daily use and 
as-needed use was not significant.31 On the other 
hand, the use of intermittent high-dose inhaled 
glucocorticoids for specified periods was more 
effective than placebo in preschool-age children 
with intermittent, recurrent wheezing12,32,33 and 
in those at high risk for asthma but with low 
levels of respiratory impairment.11 Thus, we de-
termined that a placebo group was not indicated 
for our study, which involved children who had 
low impairment but were at high risk for emerging, 
persistent asthma and recurrence of an asthma 
exacerbation, a decision that was approved by the 
independent oversight boards.
Budesonide inhalation suspension was selected 
for the daily low-dose inhaled glucocorticoid since 
it was the only such drug approved by the Food 
and Drug Administration for daily use in children 
between the ages of 1 and 4 years at recommended 
starting daily doses of 0.5 to 1.0 mg on the basis 
of pivotal trials of budesonide versus placebo in 
children between the ages of 1 and 8 years.13-15 
In post hoc analyses, daily doses of 0.5 and 1.0 mg 
of budesonide were similarly effective in children 
under the age of 4 years and in those 4 years of age 
or older.34 Budesonide in a daily dose of 0.5 mg 
was also associated with fewer exacerbations and 
less impairment than was cromolyn17 or monte-
lu kast16 in young children. The efficacy of once-
daily budesonide by nebulization (including a dose 
of 0.5 mg) has been summarized previously.35 In 
addition, guidelines recommend a daily dose of 
0.5 mg of budesonide as a low-dose inhaled gluco-
corticoid.8,23 As compared with placebo, bu des-
onide was efficacious without retarding growth 
when used in an intermittent high-dose regimen 
of 1 mg twice daily for 7 days with each respira-
tory tract illness in preschool-age children.11
Our findings may not be applicable to young 
children whose asthma was different from or 
more severe than that of the children in our 
study. Daily36 or intermittent31,37 use of inhaled 
glucocorticoids or even short courses of oral glu-
cocorticoids started at the onset of wheezing epi-
sodes38,39 may not be efficacious in preschool-age 
children with a first episode, with transient or in-
frequent wheezing, or without an asthma diagnosis 
or a high risk of asthma.
Although the observed exacerbation rates in 
the two study groups were numerically similar, 
our results do not show with certainty that the 
two treatments were equally effective. The un-
certainty is reflected in the confidence interval 
for the relative rate of exacerbations, which ex-
tends from approximately 0.7 to 1.35, so our data 
do not rule out the possibility that either treat-
ment could be up to 35% more effective than the 
other. The advantage of the intermittent regimen 
over the daily regimen cannot be based on differ-
ential effects on growth, but rather on a reduced 
exposure to inhaled glucocorticoids (approximate-
ly 100 mg less during the course of a year, or a 
reduction in exposure by a factor of 3.3). The non-
completion rate was higher than anticipated but 
similar in the two groups, as were the charac-
teristics of the children who did not complete 
the study.
A major advantage of an intermittent regimen 
of inhaled glucocorticoids is that its initiation 
occurs early during a predefined respiratory tract 
illness on the basis of individualized symptoms 
that historically have occurred before the onset 
of wheezing.11 This strategy avoids the use of in-
haled glucocorticoids for each upper respiratory 
tract illness and thus allows for the benefits of the 
regimen at considerably lower cumulative levels of 
exposure. In our study, intermittent bu des onide 
was initiated on average once every 3.5 months, in 
contrast to a monthly rate when such therapy was 
started preemptively with each upper respiratory 
tract infection.12 This finding may explain the 
adverse effects on growth in the latter study,12 
as compared with our approach.11 Nevertheless, 
parents require careful, individualized instruction 
on when to start budesonide in order to ensure 
that this intermittent approach is used appropri-
ately, as detailed previously11,19 (Fig. S2 in the Sup-
plementary Appendix).
In summary, our trial compared the efficacy 
of an early intermittent high-dose regimen of bu-
desonide for respiratory tract illness with that of 
a daily low-dose regimen, with the latter recom-
mended by current guidelines for preschool-age 
children with recurrent wheezing episodes and 
positive values on the modified API. We conclude 
that for such children who have had one or more 
exacerbations requiring the use of systemic glu-
cocorticoids, urgent or emergency medical visits, 
or hospitalizations during the previous year but 
a documented history of low impairment from 
asthma, the daily low-dose regimen of budes-
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